Neuphoria Therapeutics (NEUP) Proxy filing summary

Executive summary

• Annual meeting scheduled for November 2, 2026, to be held virtually at 9:00 a.m. Eastern Time.

• Proxy materials are available online, with options for electronic or paper delivery upon request.

• Shareholders are encouraged to review all proxy materials and vote online or by requesting a paper ballot.

Voting matters and shareholder proposals

• Election of one Class II director, Alan Fisher, for a three-year term expiring at the 2029 annual meeting.

• Ratification of Wolf & Company P.C. as independent registered public accounting firm for fiscal year ending June 30, 2027.

• Approval of potential adjournments of the annual meeting to solicit additional proxies if needed.

Board of directors and corporate governance

• Board recommends voting FOR the director nominee and FOR both other proposals on the agenda.